|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence and characteristics of anti-HCV positivity and chronic hepatitis C virus infection in HFE p.C282Y homozygotes.
|
31056361 |
2020 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C.
|
23924495 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
|
22098610 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
|
20190684 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To further examine this question, 45 liver explants with alpha-1-antitrypsin deficiency and 33 control livers with chronic hepatitis C were examined for histological iron accumulation, graded on a scale of 0 to 4+, and HFE mutations.
|
20208481 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the role of HFE mutations in the severity of liver disease and in the response to therapy in chronic hepatitis C.
|
20555268 |
2010 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the status of hepatic iron deposition and its relationship with blood iron indices, liver histology, and HFE gene mutations in Korean patients with chronic hepatitis C (CH-C).
|
19602897 |
2009 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
LHGDN |
HFE gene in primary and secondary hepatic iron overload.
|
17729389 |
2007 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this work was to assess the influence of HFE mutations and serum and hepatic measures of iron status on baseline features and response to lead-in therapy in subjects with advanced chronic hepatitis C enrolled in the Hepatitis C Anti-viral Long-term Treatment to prevent Cirrhosis (HALT-C) Trial.
|
17101320 |
2006 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
|
15991291 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The relationship of H63D HFE gene mutations with chronic hepatitis C and the possible influence of HCV infection on iron metabolism needs further analysis.
|
16273299 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relationship of H63D HFE gene mutations with chronic hepatitis C and the possible influence of HCV infection on iron metabolism needs further analysis.
|
16273299 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to describe the histopathologic features of hepatic iron accumulation in patients with chronic hepatitis C (CH-C) infection, the relation between HFE mutations and hepatic iron location and among iron distribution, HFE, and hepatic damage.
|
16416733 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
|
15991291 |
2005 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Our findings support a role of HFE mutations as primary risk factors for fibrogenesis and disease progression in chronic hepatitis C.
|
15287851 |
2004 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Histological activity and virological response to antiviral therapy (n = 146) were analysed in 273 immunocompetent and nonalcoholic patients with chronic hepatitis C, in terms of serum iron load, intrahepatic iron load (n = 110) and HFE mutations.
|
14996353 |
2004 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings support a role of HFE mutations as primary risk factors for fibrogenesis and disease progression in chronic hepatitis C.
|
15287851 |
2004 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HFE mutations must therefore be considered as important comorbidity factors in chronic hepatitis C infection.
|
15464655 |
2004 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The presence of HFE mutations is independently associated with iron loading and advanced fibrosis in patients with compensated liver disease from chronic hepatitis C, especially after controlling for duration of disease.
|
12557137 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of HFE mutations is independently associated with iron loading and advanced fibrosis in patients with compensated liver disease from chronic hepatitis C, especially after controlling for duration of disease.
|
12557137 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.
|
12586300 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relations between hemochromatosis gene (HFE) mutations and PCT in the south of France and their links with chronic hepatitis C virus (HCV) infection.
|
12673077 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heterozygosity for the C282Y mutation in HFE contributes to iron accumulation and fibrosis progression in chronic hepatitis C.
|
14557859 |
2003 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.
|
12445428 |
2002 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HFE mutations were seen in 47% of patients with chronic hepatitis C and in 28% of control subjects; they were related to stage and the His63Asp mutation to portal HDI.
|
10761457 |
2000 |